Table 3. DMDs used in the first and second treatment changes according to time period.
| Period | First treatment change (n=59) | Second treatment change (n=13) | |
|---|---|---|---|
| DMD | n (%) | n (%) | |
| Before 2010 | GA | 8 (50) | - |
| IFNβ-1a-IM | 2 (12.6) | 1 (50) | |
| IFNβ-1a-SC | 6 (37.5) | 1 (50) | |
| After 2010 | GA | 9 (20.9) | 2 (53.9) |
| Fingolimod | 12 (27.8) | 7 (15.4) | |
| IFNβ-1a-IM | 4 (9.3) | - | |
| IFNβ-1a-SC | 2 (4.7) | - | |
| Natalizumab | 8 (18.6) | 1 (7.7) | |
| Teriflunomide | 6 (14) | - | |
| Alemtuzumab | - | 1 (7.7) | |
| Dimethyl fumarate | 2 (4.7) | - | |
DMD: disease-modifying drug, GA: glatiramer acetate, IFN: interferon, IM: intramuscular, SC: subcutaneous.